Edgewise Therapeutics (EWTX) Interest Coverage Ratio (2020 - 2025)
Edgewise Therapeutics (EWTX) posted Interest Coverage Ratio of 14.73 for Q4 2025, down 48.8% sequentially from 9.9 in Q4 2024, and down 48.8% YoY from 28.77 in Q4 2024.
Edgewise Therapeutics (EWTX) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Edgewise Therapeutics has reported Interest Coverage Ratio for 6 years, with the latest figure at 14.73 in Q4 2025.
- Quarterly Interest Coverage Ratio fell 48.8% year-over-year to 14.73 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 50.37 (down 45.88% YoY) and the FY2025 annual result came in at 0.75, down 26.01% from the prior year.
- Interest Coverage Ratio slipped to 14.73 in Q4 2025 per EWTX's latest filing, from 9.9 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 3.61 in Q2 2023 and troughed at 638.91 in Q4 2023.
- A 5-year average of 72.56 and a median of 22.78 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2021 and 2024: Interest Coverage Ratio sank 12585.77% in 2021, then jumped 98.45% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 90.94 in 2021, then surged by 43.8% to 51.11 in 2022, then plunged by 1150.09% to 638.91 in 2023, then surged by 98.45% to 9.9 in 2024, then plunged by 48.8% to 14.73 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 14.73, 9.9, and 35.75 for Q4 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.73 |
| Dec 31, 2024 | -9.90 |
| Jun 30, 2024 | -35.75 |
| Mar 31, 2024 | -5.45 |
| Dec 31, 2023 | -638.91 |
| Sep 30, 2023 | -22.78 |
| Jun 30, 2023 | -3.61 |
| Mar 31, 2023 | -3.62 |
| Dec 31, 2022 | -51.11 |
| Sep 30, 2022 | -25.90 |
| Jun 30, 2022 | -36.09 |
| Mar 31, 2022 | -4.49 |
| Dec 31, 2021 | -90.94 |
| Dec 31, 2020 | -0.72 |